p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Pancreatic Cancer
Status:
Completed
Trial end date:
2017-10-30
Target enrollment:
Participant gender:
Summary
Patients with pancreatic cancer which has stopped responding to one or more chemotherapy
drugs are asked to take part in this study. The study hopes to find out whether decitabine,
the drug being studied, will have an effect on pancreatic cancer. The decitabine is being
given at a lower dose than its approved use. It is also being given with another drug,
tetrahydrouridine (THU), to improve the exposure of your pancreatic cancer cells to
decitabine.
The purpose of this study is to determine if the drug combination of decitabine and
tetrahydrouridine can recognize a certain DNA target in your cancer. All cells have DNA
within them, and tumor cells have abnormal DNA.